- Business Wire•12 hours ago
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that Sandra Poole, Executive Vice President, Technical Operations and Commercial Development, will leave the Company at the end of January to pursue other opportunities.
- Motley Fool•20 days ago
The biotech leaps ahead for no apparent reason.
- Accesswire•20 days ago
NEW YORK, NY / ACCESSWIRE / January 4, 2017 / U.S. markets posted impressive after a tumultuous start to 2016. The Dow Industrials posted its worst-ever 5-day period to being the year with a 6.2 percent ...
IMGN : Summary for ImmunoGen, Inc. - Yahoo Finance
ImmunoGen, Inc. (IMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||2.36 x 1000|
|Ask||2.52 x 400|
|Day's Range||2.38 - 2.49|
|52 Week Range||1.51 - 10.08|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|